iZafe Group AB (publ) (IZAFE-B.ST)
SEK 0.21
(-0.93%)
SEK 0.21
(-0.93%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.14 SEK | 51.72% |
| 2022 | -0.29 SEK | 65.88% |
| 2021 | -0.85 SEK | -129.73% |
| 2020 | -0.37 SEK | 65.74% |
| 2019 | -1.08 SEK | -103.77% |
| 2018 | -0.53 SEK | -51.43% |
| 2017 | -0.35 SEK | 36.36% |
| 2016 | -0.55 SEK | -96.43% |
| 2015 | -0.28 SEK | 26.32% |
| 2014 | -0.38 SEK | 56.82% |
| 2013 | -0.88 SEK | -144.44% |
| 2012 | -0.36 SEK | 51.35% |
| 2011 | -0.74 SEK | 30.19% |
| 2010 | -1.06 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q3 | -0.02 SEK | -16.88% |
| 2024 Q1 | -0.02 SEK | 67.72% |
| 2024 Q2 | -0.02 SEK | 31.25% |
| 2023 Q1 | -0.03 SEK | 44.27% |
| 2023 Q3 | -0.02 SEK | 2.53% |
| 2023 Q2 | -0.02 SEK | 31.01% |
| 2023 Q4 | -0.07 SEK | -259.59% |
| 2023 FY | - SEK | 51.72% |
| 2022 Q2 | -0.07 SEK | 25.35% |
| 2022 FY | - SEK | 65.88% |
| 2022 Q3 | -0.08 SEK | -10.2% |
| 2022 Q1 | -0.10 SEK | 16.83% |
| 2022 Q4 | -0.05 SEK | 37.27% |
| 2021 Q2 | -0.24 SEK | 7.69% |
| 2021 Q4 | -0.12 SEK | 29.41% |
| 2021 Q1 | -0.26 SEK | 0.0% |
| 2021 FY | - SEK | -129.73% |
| 2021 Q3 | -0.17 SEK | 29.17% |
| 2020 Q2 | -0.15 SEK | 6.25% |
| 2020 Q1 | -0.16 SEK | 52.94% |
| 2020 Q4 | -0.26 SEK | -230.0% |
| 2020 FY | - SEK | 65.74% |
| 2020 Q3 | 0.20 SEK | 233.33% |
| 2019 Q2 | -0.35 SEK | -12.9% |
| 2019 FY | - SEK | -103.77% |
| 2019 Q3 | -0.19 SEK | 45.71% |
| 2019 Q4 | -0.34 SEK | -78.95% |
| 2019 Q1 | -0.31 SEK | -82.35% |
| 2018 Q2 | -0.30 SEK | -42.86% |
| 2018 FY | - SEK | -51.43% |
| 2018 Q1 | -0.21 SEK | -16.67% |
| 2018 Q3 | -0.15 SEK | 50.0% |
| 2018 Q4 | -0.17 SEK | -13.33% |
| 2017 Q2 | -0.07 SEK | -64.06% |
| 2017 Q3 | -0.10 SEK | -36.24% |
| 2017 Q4 | -0.18 SEK | -85.57% |
| 2017 FY | - SEK | 36.36% |
| 2017 Q1 | -0.04 SEK | -461.67% |
| 2016 Q3 | -0.09 SEK | 84.26% |
| 2016 FY | - SEK | -96.43% |
| 2016 Q2 | -0.57 SEK | -637.39% |
| 2016 Q1 | -0.08 SEK | -7.36% |
| 2016 Q4 | 0.01 SEK | 113.38% |
| 2015 Q4 | -0.07 SEK | 0.0% |
| 2015 Q2 | -0.08 SEK | 0.0% |
| 2015 Q1 | -0.08 SEK | 33.0% |
| 2015 FY | - SEK | 26.32% |
| 2015 Q3 | -0.07 SEK | 10.45% |
| 2014 FY | - SEK | 56.82% |
| 2014 Q4 | -0.12 SEK | -33.48% |
| 2014 Q2 | -0.09 SEK | 6.74% |
| 2014 Q1 | -0.10 SEK | 83.41% |
| 2014 Q3 | -0.09 SEK | 1.53% |
| 2013 Q3 | -0.05 SEK | 68.18% |
| 2013 FY | - SEK | -144.44% |
| 2013 Q4 | -0.59 SEK | -990.57% |
| 2013 Q1 | -0.09 SEK | 27.85% |
| 2013 Q2 | -0.17 SEK | -81.24% |
| 2012 Q2 | -0.08 SEK | 31.5% |
| 2012 FY | - SEK | 51.35% |
| 2012 Q1 | -0.12 SEK | 0.0% |
| 2012 Q4 | -0.13 SEK | -102.49% |
| 2012 Q3 | -0.06 SEK | 21.9% |
| 2011 FY | - SEK | 30.19% |
| 2010 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AddLife AB (publ) | 1.56 SEK | 108.974% |
| Biotage AB (publ) | 3.33 SEK | 104.204% |
| Bonesupport Holding AB (publ) | 3.77 SEK | 103.714% |
| Doxa AB (publ) | 0.60 SEK | 123.333% |
| Elekta AB (publ) | 3.41 SEK | 104.106% |
| Ortivus AB (publ) | -0.41 SEK | 65.854% |
| Ortivus AB (publ) | -0.41 SEK | 65.854% |
| Q-linea AB (publ) | -3.48 SEK | 95.977% |
| S2Medical AB (publ) | -0.14 SEK | -0.0% |
| Synsam AB (publ) | 2.09 SEK | 106.699% |